Pancreatic islet inflammation: an emerging role for chemokines

J Jason Collier1, 2, Tim E Sparer3, Michael D Karlstad2 and Susan J Burke4

1Laboratory of Islet Biology and Inflammation, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
2Department of Surgery, Graduate School of Medicine, University of Tennessee Health Science Center, Knoxville, Tennessee, USA
3Department of Microbiology, University of Tennessee, Knoxville, Knoxville, Tennessee, USA
4Laboratory of Immunogenetics, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

Correspondence should be addressed to J J Collier
Email Jason.collier@pbrc.edu

Key Words
- cytokine
- chemokine
- diabetes
- islet
- inflammation

Abstract
Both type 1 and type 2 diabetes exhibit features of inflammation associated with alterations in pancreatic islet function and mass. These immunological disruptions, if unresolved, contribute to the overall pathogenesis of disease onset. This review presents the emerging role of pancreatic islet chemokine production as a critical factor regulating immune cell entry into pancreatic tissue as well as an important facilitator of changes in tissue resident leukocyte activity. Signaling through two specific chemokine receptors (i.e., CXCR2 and CXCR3) is presented to illustrate key points regarding ligand-mediated regulation of innate and adaptive immune cell responses. The prospective roles of chemokine ligands and their corresponding chemokine receptors to influence the onset and progression of autoimmune- and obesity-associated forms of diabetes are discussed.

Introduction
Development of diabetes mellitus is currently classified based on the route by which hyperglycemia develops. Presently, type 1 diabetes (T1D) is described as an autoimmune disease that results when the function and/or mass of the insulin-producing β-cells is reduced to a degree that produces clinical symptoms (e.g., hyperglycemia, polyuria, etc.; see Atkinson et al. 2014). Type 2 diabetes (T2D) is described as a more slowly progressing disease characterized first by insulin resistance and glucose intolerance, two conditions that indicate ‘pre-diabetes’ (Johnson & Olefsky 2013, Cefalu et al. 2014, Cefalu 2016). The pre-diabetes stage progresses to overt clinical onset of diabetes when the function and mass of the islet β-cells decrease to the point where the ability to maintain glucose homeostasis is ultimately lost (Kahn 1998, Doria et al. 2008, Muoio & Newgard 2008). At present, the hallmark of each disease appears to be dysfunction of the islet β-cell population, a reduction in total numbers of insulin-producing cells or both outcomes.

While the specific subclasses of diabetes are delineated by their individual etiological associations accompanying islet β-cell death and dysfunction, there are changes in the genetic programming of β-cells during progression to each form of diabetes that contribute to and influence disease progression (Cnop et al. 2014, Donath 2014, Lopes et al. 2014, Burke & Collier 2015, Sanchez et al. 2015). This transcriptional reprogramming is occasionally overlooked although it is an important contributor to disease progression and outcome. Precise signaling inputs control these genetic effects with the major alterations in gene transcription connected to the production of molecules that regulate cellular viability, influence immune cell recruitment, impact glucose-stimulated calcium dynamics and eventually reduce maximal glucose-mediated insulin
secretion. The end result is an overall diminution in either insulin-positive cell mass, circulating insulin levels or both. Despite distinct etiologies for T1D and T2D, understanding the pathophysiological mechanisms of each disease will likely benefit the development of therapies to treat both diseases. Thus, we begin by briefly outlining some of the noteworthy similarities between T1D and T2D to illustrate that significant parallels exist between these common endocrine diseases.

Parallels between T1D and T2D

Autoimmunity is a key driver of T1D (Castano & Eisenbarth 1990), while obesity is one of the most important risk factors for the development of T2D (Bray 1992). However, there are a number of commonalities between T1D and T2D that are worth considering. First, insulin resistance is a risk factor for both T1D (Fourlanos et al. 2004, Donga et al. 2015) and T2D (Kahn 1998, Samuel & Shulman 2016). Second, pro-inflammatory cytokines (e.g., IL-1β, IFN-γ, TNF-α, etc.) contribute to the disease phenotype in both T1D and T2D (Dogan et al. 2006, Donath 2014, Burke et al. 2015b). Third, advanced glycation end products are present in both T1D (Coughlan et al. 2011, Forbes et al. 2009) and T2D (Nowotny et al. 2015). Fourth, insulin therapy is indicated for therapeutic intervention during specific stages of each disease (Atkinson et al. 2014, Home et al. 2014, Kreider & Lien 2015). Fifth, there are altered circulating levels of various chemokines in both T1D and T2D (Hanifi-Moghaddam et al. 2006, Shigihara et al. 2006, Takahashi et al. 2011, Sajadi et al. 2013, Corrado et al. 2014, Nunemaker et al. 2014, Burke & Collier 2015). Sixth, there are defects in insulin secretion and calcium usage in rodent and human islets associated with T1D and T2D (Boucher et al. 2004, Dula et al. 2010, Ramadan et al. 2011, Do et al. 2014, Burke et al. 2015b, Kenty & Melton 2015, Qureshi et al. 2015). Seventh, immune cells infiltrate the islets in both T1D and T2D (Gepts 1965, Ehses et al. 2007, Boni-Schnetzler et al. 2008, Richardson et al. 2009, Willcox et al. 2009, Burke et al. 2016). With this last point in mind, we note that excellent reviews exist discussing the immunology of diabetes (Castano & Eisenbarth 1990, Wallberg & Cooke 2013, Boldison & Wong 2016). Therefore, we will focus this review around pancreatic islet β-cell chemokine production with a discussion of two important chemokine receptor-signaling paradigms that fundamentally impact specific subsets of immune cells known to participate in the pathogenesis of T1D and T2D.

Chemokines: soluble secreted proteins that regulate immune cell movement and activity

Chemotactic cytokines (aka chemokines) are a family of small (8–10kDa), secreted, signaling proteins that have biological impact through activation of their specific cell surface receptors. These receptor-mediated actions include the directed chemotaxis of a responsive target cell, changes in intracellular second messengers, and the ability to influence gene expression, protein localization, protein production and secretion of molecules relevant to immune cell function (Charo & Ransohoff 2006). Chemokines are currently classified by their structural characteristics and are divided into different families based on the spacing of their N-terminal cysteines (i.e., CC, CXC, CX3C or C). Chemokines as a group are usually sub-classified into homeostatic or pro-inflammatory categories, with many present in both groups. These proteins direct leukocyte migration and influence immune cell activity. Their contribution to development, onset, maintenance and resolution of various disease processes constitute active research areas.

Chemokines are protein ligands for their cognate chemokine receptors, which are members of the much larger G protein coupled receptor (GPCR) superfamily. Upon ligand binding to the chemokine receptor, a conformational change leads to the exchange of GDP with GTP and the activation of the heterotrimeric G proteins (Pierce et al. 2002). These heterotrimeric G proteins consist of 21, 6 and 12 different Gα, β, and γ subunits, respectively, which contribute to the complexity of signaling outputs. The downstream effects of GPCR activation is dictated by signal strength and subsequent effects on the receptors: internalization (Marchese et al. 2008), intracellular location (Jiao et al. 2005), hetero/homo-dimerization (Trettel et al. 2003, Wilson et al. 2005, Martinez Munoz et al. 2009) and G protein subunit usage (Khan et al. 2013, Syrovatkina et al. 2016). In addition, the desensitization and inactivation of the intracellular signal also affects signaling outcomes. G protein receptor kinases (GRKs) and β-arrestins turn off the signaling of individual chemokine receptors.

Interestingly, β-arrestins can also induce their own downstream signaling outcomes (Luttrell & Lefkowitz 2002, Shenoy & Lefkowitz 2005, Defea 2008), with the levels of the desensitizing proteins and their isoforms affecting the overall signaling mechanisms. For example, CXCR1 and CXCR2 bind to GRK2 and GRK6, respectively, which produce differences in neutrophil
activation (Raghuvanshi et al. 2012). Discrete activation mechanisms allow for fine-tuning of the chemokine signaling pathways, an important observation bearing in mind there are ~50 associated chemokine ligands that impact ~20 different chemokine receptors. Most of the chemokine receptors display promiscuous interaction with multiple chemokines, which was initially thought as redundancy in the biological setting. However, in light of recent data on chemokine receptor activation linked to specific biological responses, a more complex picture has formed showing multiple different stimuli at the same receptor trigger differential downstream effects (Zweemer et al. 2014). In other words, one receptor can produce distinct outcomes depending on which ligand occupies the binding site. This updated paradigm is often referred to as biased signaling, biased agonism or functional selectivity (Wisler et al. 2014, Karin et al. 2016).

In the case of both T1D and T2D, we postulate that the most logical biochemical and immunological explanation for the initial and sustained entry of one or more immune cell populations into pancreatic tissue is directed chemotaxis by specific signaling molecules (e.g., chemokines). Because increased immune cell presence within pancreatic tissue occurs as part of the phenotype underlying T1D and T2D (Foulis & Stewart 1984, Foulis et al. 1991, Boni-Schnetzler et al. 2008, Donath et al. 2008, Hanafusa & Imagawa 2008), we and others have focused a significant portion of our research efforts into understanding the inflammation-associated processes related to islet chemokine production and secretion. Below, we provide a brief discussion of signaling through two representative chemokine receptors relevant to innate and adaptive immunity.

**Chemokine ligand activation of chemokine receptors in innate and adaptive immunity**

Pancreatic β-cells synthesize and secrete a variety of chemokines capable of recruiting leukocytes into pancreatic tissue (Sarkar et al. 2012). The expression of many of these chemokines is markedly enhanced by β-cell exposure to inflammatory signals (Sarkar et al. 2012, Cnop et al. 2014, Lopes et al. 2014, Burke & Collier 2015). Below, we focus on ligand-mediated signaling events associated with CXCR2 and CXCR3, which are two specific chemokine receptors reported to influence onset and progression of diabetes. These two receptors are also important because they exemplify enriched expression in neutrophils (CXCR2) and T-cells (CXCR3). Because β-cell exposure to inflammatory mediators induces various chemokine ligands that bind to CXCR2 and CXCR3 (Burke et al. 2014, 2015a,b, 2016), we discuss what is known about the activation pathways of these two receptors and the downstream effector mechanisms that contribute to immune activation and subsequent β-cell destruction.

**CXCR2**

CXCR2 is highly expressed on neutrophils (Murphy & Tiffany 1991, Liu et al. 2010) and oligodendrocytes (Veenstra & Ransohoff 2012). It is expressed less consistently on T cells, basophils, mast cells and epithelial cells during wound healing. CXCR2 binds ELR-CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8) with high affinity. CXCR1 binds CXCL8 with high affinity, while CXCL6 and CXCL7 bind less well to CXCR1 than to CXCR2 (Waugh & Wilson 2008). In the case of CXCR2, this biased agonism (or functional selectivity) was initially thought of as redundancy for receptor activation. However, distinct and complex signaling crosstalk produces different phenotypic responses and is now thought to be important for physiological and pathophysiological outcomes (Zweemer et al. 2014).

For CXCR2 activation, specific chemokines bind and activate the receptor via the amino terminus and first extracellular loop. Site directed mutagenesis in these regions generates different activation and functional consequences (Katancik et al. 1997, Katancik et al. 2000). The receptor-associated signal is transduced to the second intracellular loop where the G proteins are bound to the aspartic acid, arginine and tyrosine (DRY) box and leads to the GDP to GTP exchange and G protein activation. After activation the carboxyl terminus is phosphorylated on the LLKIL motif, which leads to activation of the β-arrestins and internalization/desensitization (Raman et al. 2014). The receptor is then targeted to different endosomal compartments based on its phosphorylation state for degradation or recycling. These varied signals from CXCR2 stimulation initiate intracellular Ca2+ flux, inhibition of apoptosis, migration, priming and adhesion depending on the downstream signaling pathway that is activated (Mocsai 2013). Neutrophil recruitment via CXCR2 is critical for the autoimmune responses targeting islet β-cells; inhibiting CXCR2 partially blocks this outcome (Citro et al. 2012, Diana & Lehuen 2014).

Moreover, neutrophils and CXCR2 signaling during diabetes development were shown in the NOD mouse model, which develops T1D spontaneously with many
features of the human disease. When CXCR2 was inhibited or neutrophils were depleted, disease progression was limited in these mice (Diana et al. 2013, Citro et al. 2015). Additional evidence showing that allosteric inhibitors of CXCR2/CXCR1 lead to prolonged survival of islet transplants in both mice and humans confirms the importance of neutrophil chemokine/chemokine receptor activation during disease onset (Citro et al. 2012). Using neutrophil elastase inhibitors, Talukdar et al. demonstrated that neutrophils also impact obesity-induced insulin resistance (Talukdar et al. 2012). Taken together, these data illustrate the promise of CXCR2- and/or neutrophil-based immunomodulatory strategies as possible treatments for pathological responses that contribute to the onset of T1D and T2D.

CXCR3

The interferon (IFN)-inducible, non-ELR CXC chemokine subgroup includes CXCL9 (Mig), CXCL10 (IP10) and CXCL11 (I-TAC), which are proteins that bind to CXCR3 (Groom & Luster 2011). This receptor is mainly found on NK cells and T cells and has a role in a variety of diseases, especially those with a Th component (Van Raemdonck et al. 2015). When CXCL10 is expressed in the islets of transgenic mice, an accelerated autoreactive immunological response was observed (Rhode et al. 2005). In addition, islet isografts were protected when CXCL10 expression was diminished (Bender et al. 2017). Serum CXCL10 levels are increased in both human subjects and in the NOD mouse model, linking elevated chemokine production with diabetes (Christen et al. 2003, Antonelli et al. 2014, Corrado et al. 2014). When CXCR3 is knocked out, there is a delay in the onset of virally induced diabetes (Frigerio et al. 2002) and in diabetes induced by multiple low doses of streptozotocin (Burke et al. 2016). By contrast, when CXCR3 null mice are crossed onto the NOD background, T1D development is accelerated (Yamada et al. 2012). What appear to be contrary findings could be due to genetic differences in the different mouse strains, the distinct models of T1D or functional selectivity of CXCR3 activation that is related to strain and/or the models of diabetes.

It is important to note that mice on a C57BL/6 background do not produce CXCL11 due to an insertion of 2 bases after nucleotide 39, which shifts the open reading frame of the CXCL11-encoding gene to a premature stop codon (Sierro et al. 2007). By contrast, the NOD mice retain the ability to produce CXCL11, which could explain differences in whole body phenotypes observed between knockouts of CXCR3 when compared with C57BL/6 mice. In the viral model of T1D, knocking out ligands binding to CXCR3 showed redundancy instead of biased agonism, i.e., knocking out one of the CXCR3 ligands had no effect (Coppitieters et al. 2013), leaving us to speculate how the individual ligands contribute to onset and progression of diabetes. Along these lines, the different chemokine ligands that bind CXCR3 show biased agonism during in vitro studies. Watts and coworkers used impedance measurements, BRET and CRE luciferase assays to show that CXCL9 induces β-arrestin binding and produces higher impedance measurements when compared with CXCL10 and CXCL11 (Watts et al. 2012). Conversely, Rajagopal and coworkers showed bias only for CXCR3 for internalization, with CXCL11 the more potent agonist when compared with CXCL9 and CXCL10 (Rajagopal 2013, Rajagopal et al. 2013). Although the signaling pathways activated after differential ligand binding have not been fully elucidated, there are some clues about CXCR3 signal transduction cascades that are informative. For example, the differential downstream signaling is due, at least in part, to differential Gα subunit usage (Kouroumalis et al. 2005, Thompson et al. 2007). CXCL10 stimulation of CXCR3 also leads to activation of the ERK/Ras pathway and an increase in migration and signaling (Bonacchi et al. 2001).

Decoding the chemokine receptor signaling pathways could allow for drugs that have functional selectivity for some of the beneficial phenotypes while ideally eliminating the detrimental outcomes. One clue to the importance of specific pathways on diabetes development came from nucleotide-binding leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) knockout mice; NLRP3 functions as part of the innate immune system via pattern recognition responses (Martinon 2008). In NLRP3−/− mice, expression of CXCR3, and the corresponding ligands, CXCL9 and CXCL10, were decreased (Hu et al. 2015). The expression of other chemokines and their receptors was also reduced. Importantly, diabetes took longer to develop in NLRP3−/− mice, implying that these chemokines and associated receptors contribute to T1D development.

On a related note, the small molecule CXCR3 antagonist, SCH 546738, was shown to prevent autoimmune diseases (Jenh et al. 2012), while another CXCR3 inhibitor, NBL-74330, had distinct potencies for the different CXCR3 ligands (Heise et al. 2005). Whether this information regarding functional selectivity will be useful for the design of new therapeutics aimed at modulating human CXCR3 pathways during autoimmune diseases remains to be revealed. It will be of particular interest to
determine whether any of the existing molecules targeting chemokine receptors directly have therapeutic benefit in the different models of diabetes.

**Islet-derived chemokines in T1D**

Genes encoding chemokines are located within the known diabetes susceptibility locus Idd4 in the NOD mouse, which is associated with T1D development (Grattan et al. 2002). While the initial trigger(s) prompting the onset of β-cell directed autoimmunity is unknown, enhanced production and release of chemokines from pancreatic islets coupled with the associated chemokine receptor activation on individual leukocytes is a very plausible component of the disease course. The following components are proposed to be contributors to T1D development: (1) secretion of cytokines and chemokines by resident immune cells (e.g., macrophages) in response to a specific pathogen or pathogenic signal (e.g., death of surrounding cells, viral infection, LPS, etc.); (2) the production of islet-derived chemokines increases in response to such signals, promoting the recruitment of additional immune cell populations (e.g. neutrophils, T-cells, etc.) into the pancreatic islets; (3) T-cell priming for one or more antigens (typically β-cell specific); (4) chemokine-mediated entry of primed lymphocytes into the pancreatic tissue; (5) continued production and release of cytokines (e.g., IL-1β, IFN-γ, etc.) that regulate inflammatory responses, including immune cell activity, within pancreatic islets; and (6) sustained production of chemokines, including from pancreatic β-cells, creating a vicious feed forward cycle intended to either clear infection or promote tissue repair (physiological outcome) that transitions during chronic disease states (e.g., autoimmunity) to become pathophysiological. Portions of this model have been validated using transgenic mouse models where production of CCL2 or CXCL10 directly from pancreatic islets (Grewal et al. 1997, Rhode et al. 2005, Martin et al. 2008b) and by reducing chemokine action via decoy receptor expression in NOD mice (Martin et al. 2008a).

T1D arises through multiple immune cell interactions, including macrophages, neutrophils and T-cells (Calderon et al. 2006, Diana et al. 2013). This means various innate and adaptive immune cells, and molecules secreted from such cells, all participate and contribute in some capacity to the disease pathology. Thus, signals contributing to immune cell recruitment, such as chemokines, are critical players in initiating, accelerating and/or maintaining disease trajectory. Consistent with this idea, IL-1α and TNF-α are elevated in ‘at risk’ and new onset T1D subjects when compared with healthy controls (Rosa et al. 2008, Chatzigeorgiou et al. 2010, Zak et al. 2010). IL-1α and TNF-α signal through the IL-1 receptor and TNF receptor, respectively, both of which activate the NF-κB pathway. NF-κB activation drives production of multiple chemokines in islet β-cells (Burke & Collier 2014, 2015) and reduces insulin secretion in rodent and human islets (Giannoukakis et al. 2000, Rehman et al. 2003, Rink et al. 2012, Burke et al. 2015b). Conversely, restricting NF-κB activity in the multiple low dose streptozotocin (MLDS) model reduces chemokine production and protects against hyperglycemia (Eldor et al. 2006). In an alternative approach, blocking chemokine action using decoy receptors also revealed key roles for chemokine proteins in the pathogenesis of diabetes development (Martin et al. 2007, 2008a).

When examining rodent models of T1D (Tables 1 and 2), the production and release of CXCL9 and CXCL10 protein in islets from 4 and 10-week-old NOD mice correlated with the degree of insulitis (Welzen-Coppens et al. 2013). Blocking CXCL10 activity with neutralizing antibodies prevented re-infiltration of pancreatic islets after a course of anti-CD3 therapy (Lasch et al. 2015). Because T-cells primed with autoantigens typically produce and secrete IFN-γ, targeted upregulation of CXCL10 by IFN-γ signaling in β-cells is likely contributing to T1D disease pathology (Burke et al. 2013a, 2016, Lundberg et al. 2016). The enhanced transcription of the CXCL10 gene is also consistent with heightened STAT1 activity in islet β-cells (Burke et al. 2013a, Lundberg et al. 2016). Moreover, pro-inflammatory cytokines (e.g., IL-1β,

### Table 1: Islet chemokines in monogenic rodent models of obesity and diabetes.

<table>
<thead>
<tr>
<th>Animal model (species)</th>
<th>Relevant human condition</th>
<th>Islet chemokine production</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akita (mouse)</td>
<td>ER stress/insulin insufficiency</td>
<td>No&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Burke SJ (unpublished observations)&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>db/db (mouse)</td>
<td>Obesity/T2D</td>
<td>Yes</td>
<td>Eguchi et al. (2012), Burke et al. (2015a)</td>
</tr>
<tr>
<td>KKAa (mouse)</td>
<td>Obesity/T2D</td>
<td>Yes</td>
<td>Eguchi et al. (2012)</td>
</tr>
<tr>
<td>ZDF (rat)</td>
<td>Obesity/T2D</td>
<td>Yes</td>
<td>Jourdan et al. (2013)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Male mice at 8 weeks of age.

<sup>3</sup>SJ Burke, MD Karlstad & JJ Collier, unpublished observations.
IFN-γ, etc.) increase the expression of CXCL9 and CXCL11 in mouse, rat, and human β-cells using activated STAT1 as a key component of the signaling response (Burke et al. 2016). STAT1 is therefore a key driver of chemokine production (Burke et al. 2013a, 2016) and inducible nitric oxide synthase abundance and activity (Burke et al. 2013b, 2015b, Corbett et al. 1992, 1993, Heitmeier et al. 1997). Increased STAT1 expression is also strongly correlated with HLA class I (i.e., HLA-ABC) and HLA-F isoforms in insulin-containing islets (Richardson et al. 2016). Thus, NF-κB and STAT1 likely cooperate to control inflammatory responses within pancreatic islets, which ultimately determine the autoimmune and auto-inflammatory outcomes (Fig. 1). The model shown in Fig. 1 offers an attractive conceptual framework from which to explain why individual immunomodulatory approaches may have underachieved from a therapeutic perspective.

One such example of a promising single immunomodulatory strategy that has thus far failed to produce remission, or prevent T1D, in mice is anti-IL-1β neutralization (Gill et al. 2015). Although it was promising that human subjects with recent onset T1D receiving a targeted anti-IL-1 therapeutic (Anakinra) displayed reduced insulin requirements one and four months after diagnosis compared to controls (Sumpter et al. 2011), in a larger study, IL-1 neutralization strategies were not effective at meeting the clinical endpoints (Moran et al. 2013). It is worth noting, however, that one month after diagnosis the insulin-dose-adjusted A1c in patients given Anakinra was lower than controls (Sumpter et al. 2011).

Multiple explanations might exist to explain these initially disappointing findings. The first is that the neutralization or trap strategies do not completely block signaling through the IL-1 receptor, which has two known agonist ligands (i.e., IL-1α and IL-1β). The second explanation is that other signals, such as TNF-α or ligands that activate pattern recognition receptors (PRR), can still activate NF-κB despite interventions that restrict signaling through the IL-1 receptor (Fig. 1). The third explanation is that signaling through specific receptors, such as IL-1R1, may have both physiological and pathological outcomes and that receptor antagonism eliminates both positive and negative outcomes.

We note that NF-κB activation by a variety of inflammatory pathways, in conjunction with elevated levels of STAT1 and/or enhanced STAT1 transcriptional responses, would likely support sustained production of soluble factors (e.g., chemokines) that influence immune cell recruitment. In addition, the powerful combination of NF-κB and STAT1 activation regulates other key genes

### Table 2: Islet chemokines in polygenic rodent models of obesity and diabetes.

<table>
<thead>
<tr>
<th>Animal model (species)</th>
<th>Relevant human condition</th>
<th>Islet chemokine production</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>BB (rat)</td>
<td>Autoimmunity/T1D</td>
<td>Yes</td>
<td>Kuttler et al. (2007)</td>
</tr>
<tr>
<td>GK (rat)</td>
<td>Insulin resistance/T2D</td>
<td>Yes</td>
<td>Ehses et al. (2009)</td>
</tr>
<tr>
<td>MLD5 (mouse/rat)*</td>
<td>Insulin insufficiency/T1D</td>
<td>Yes</td>
<td>Martin et al. (2007, 2008a), Burke et al. (2016)</td>
</tr>
<tr>
<td>NOD (mouse)</td>
<td>Autoimmunity/T1D</td>
<td>Yes</td>
<td>Martin et al. (2008a), Welzen-Coppens et al. (2013), Burke et al. (2016)</td>
</tr>
</tbody>
</table>

*MLDS, multiple low doses of streptozotocin (STZ). STZ impacts multiple mouse and rat strains; thus, we have included it under the polygenic models.

---

Figure 1

Signals that activate NF-κB and STAT1 enhance chemokine production within pancreatic islets that contribute to the inflammatory response influencing both insulin secretion and total β-cell mass. Many signals converge on the NF-κB and STAT1 pathways to coordinately reprogram β-cells at a transcriptional level, leading to inflammation-based changes in insulin secretion, β-cell mass or both. PRRs can be either cell surface based, such as Toll-like receptor-2 and -4 or positioned intracellularly (e.g., Toll-like receptor-3, NOD1, NOD2, etc.). TNF-α and IL-1 signal through specific cell surface receptors (receptor not shown) and converge on the NF-κB pathway. The interferon family of cytokines signals through cell surface receptors that activate JAK-STAT pathways. Activation of COX2 produces prostaglandins, which may influence leukocyte activity. Cytokine-mediated increases in iNOS elevate intracellular production of nitric oxide, which acts as a rheostat for insulin secretion. COX2, cyclooxygenase-2; IFNs, interferons alpha, beta and gamma; iNOS, inducible nitric oxide synthase; PRR, pattern recognition receptors.
relevant to islet β-cell function and dysfunction (Fig. 1). Consequently, in our view, combination therapies may end up providing the most benefit to prevention of autoimmune diseases, such as T1D, by restricting signaling of multiple pathways that collectively contribute to chemokine production, and other important mediators of inflammation, which ultimately regulate islet β-cell function and mass.

**Islet-derived chemokines in T2D**

Multiple models of rodent obesity and diabetes display elevations in islet chemokine production (Tables 1 and 2). In addition, staining of human pancreatic tissue revealed high levels of CXCL10 in islets from subjects with T2D (Schulthess et al. 2009) while RNA sequencing approaches showed the expression of multiple chemokines in human islets exposed to the fatty acid palmitate (Cnop et al. 2014). These data are consistent with enhanced leukocyte presence in human pancreatic tissue during obesity (Boni-Schnetzler et al. 2008, Donath et al. 2008). Schulthess and coworkers suggest that CXCL10 signals through TLR4 on β-cells as a mechanism for deleterious effects during obesity (Schulthess et al. 2009). While an intriguing possibility, these observations still await independent verification.

On the other hand, genetic deletion of the CX3CR1 receptor reduces insulin secretion in response to the physiological signals glucose and GLP-1 (Lee et al. 2013). The chemokine CX3CL1 (aka fractalkine), which signals through CX3CR1, is decreased in islets during aging and obesity (Lee et al. 2013). It is therefore possible that particular chemokines promote β-cell health, either by recruiting specific immune cells, through direct effects on β-cells, or both. In addition to mechanisms that support leukocyte recruitment and production of pro-inflammatory cytokines, loss of these ‘protective’ or homeostatic chemokines might be a mechanism which also contributes to β-cell dysfunction during progression to T2D.

**Obesity and islet inflammation**

How does obesity trigger islet inflammation? Since no one mechanism has emerged to explain all observations, we put forth two conceptual possibilities. The first is that obesity negatively influences gut barrier function, allowing translocation of bacterial products initially into the mesenteric lymphatic system and then into the systemic circulation (Fig. 2A). This elevation in lipopolysaccharide (LPS), or other molecules that signal through pattern recognition receptors, may contribute to the subclinical, low grade inflammation that drives insulin resistance and associated tissue dysfunction (Carneiro et al. 2008, Purohit et al. 2013, Cox et al. 2015). With this in mind, it is conceivable that islet resident macrophages become activated during obesity due to elevated levels of circulating LPS derived from increased intestinal permeability (i.e., ‘leaky gut’). The presence of LPS increases macrophage cytokine production and also enhances macrophage sensitivity to IFN-γ (Held et al. 1999).

IFN-γ is a cytokine that activates macrophages and also promotes the differentiation of immature DCs into effector DCs that heavily influence Th1 responses (Boehm et al. 1997). These biological responses are intended to induce robust anti-bacterial activity, but may be dysregulated during obesity. Indeed, CXCL8, CXCL10 and IFN-γ increase in circulation with excess body weight (Straczkowski et al. 2002, Sharabiani et al. 2011). Consequently, it is plausible that bacterial translocation from a leaky gut results in a low level of LPS that, in combination with elevations in other circulating factors linked with inflammation, promotes detrimental changes in pancreatic islets. Macrophage cytokine production is a key component that impacts pancreatic islet function and mass (Fig. 2A). While speculative, this mechanism fits with existing observations put forth in the literature (Balzan et al. 2007, Cani & Delzenne 2007, Cani et al. 2007).

The second conceptual possibility explaining how obesity leads to islet inflammation is lipid overload and associated metabolic trauma (Fig. 2B). In this model, lipids accumulate in lean tissues once storage in adipose tissue has been exceeded (Unger & Orci 2000, Unger 2003). Lean tissue responses to surplus fatty acids may vary. For example, fatty acids promote macrophage activation as well as chemokine production in pancreatic islets (Eguchi et al. 2012), potentially via cell surface (e.g., TLR4) or intracellular (e.g., NOD1, NOD2, etc.) pattern recognition receptor signaling (Fig. 1). Moreover, incomplete fatty acid oxidation products drive enhanced NF-κB activity in macrophages, promoting pro-inflammatory actions (Rutkowski et al. 2014). If such incomplete fatty acid oxidation mechanisms also occur in β-cells, it could help to explain lipid-induced changes in β-cell insulin secretion as well as chemokine production that occur in obesity (Burke et al. 2015b, Eguchi et al. 2009,
This is important because the increase in β-cell chemokine production by inflammatory signals coincides with diminutions in insulin secretion (Burke et al. 2015b).

Moreover, accumulation of excess lipid within β-cells impairs insulin secretion, at least in part, by interfering with metabolic coupling steps, such as pyruvate cycling (Boucher et al. 2004). Reducing the lipid burden or restoring pyruvate cycling improves islet β-cell secretory function (Shimabukuro et al. 1998, Boucher et al. 2004). Finally, intracellular lipid accumulation in the islet β-cell may also result in ER stress. Induction of mild ER stress induces β-cell proliferation (Sharma et al. 2015), while lipid signaling through pattern recognition receptors likely reduces β-cell function and promotes production of molecules, such as chemokines and cytokines, that modulate immune cell recruitment and inflammation (Boni-Schnetzler et al. 2009).

Thus, multiple signaling mechanisms may exist to limit insulin secretion while augmenting chemokine production within pancreatic islets (and other tissues), driving increased immune cell infiltration and therefore influencing the status of pancreatic inflammation. Because increased numbers of immune cells have been observed within pancreatic islets from both rodents and humans during obesity validate these findings as conserved, important phenotypes (Ehses et al. 2007,
Bonischätzler et al. 2008, Donath et al. 2008). However, it is important to note that any immune cell entry into the pancreatic tissue is often heterogeneous. In addition, changes in the tissue resident immune cell activation state (e.g., M2 M1), without enhancements in immune cell number, could also drive inflammation-mediated changes in tissue function (Burke & Collier 2014).

Consistent with changes in leukocyte number or activation state, increased presence of chemokine ligands has been documented in pancreatic islets of mice, rats and humans during obesity (Donath et al. 2008, Schulthess et al. 2009, Eguchi et al. 2012, Sajadi et al. 2013, Burke et al. 2015a). While there is no doubt that obesity is a major risk factor for the development of T2D, the molecular determinants explaining the increased risk are still being investigated. Our view is that pancreatic islet-derived chemokines play critical roles by regulating immune cell flux into the pancreatic islets, influencing the activation state of resident immune cells or both. These outcomes ultimately impact β-cell substrate metabolism linked with insulin secretion as well as influencing proliferation of insulin-producing cells.

Summary and conclusion

A role for elevated chemokine production within β-cells as a critical mechanistic determinant controlling islet inflammation during T1D and T2D development is emerging (Tables 1 and 2). Chemokines, and other proteins that regulate inflammation, can be induced by a variety of signals that activate either STAT1, NF-κB or both signaling pathways (Fig. 1). The increased synthesis and secretion of discrete chemokines induce receptor-mediated signals that regulate immune cell entry into, and activity within, pancreatic tissue (Fig. 2). Importantly, chemokine production in pancreatic islets appears to be a common phenomenon between T1D and T2D. While rodent work has been incredibly informative towards understanding the genetics and phenotypes of the human disease, much remains to be uncovered. It is our hope that understanding the inflammatory signaling-induced upregulation of chemokine production and chemokine/chemokine receptor interactions will assist in the design of therapeutics relevant to improving β-cell mass and secretory function as a way to combat the growing incidence of T1D and T2D.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

Work in the authors’ laboratories was supported by NIH grants P20 GM103528 (J J C), P30 GM118430 (J J C), R44 GM099207 (J J C and M D K) and R01 AI071042 (T E S).

References


Burke SJ, Golf MR, Lu D, Proud D, Karlstad MD & Collier JJ 2013a Synergistic expression of the CXCL10 gene in response to IL-1β and IFN-γ/IFN-γ involves NF-κappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4. Journal of Immunology 191 323–336. (doi:10.4049/jimmunol.1300344)


Cefalu WT 2016 ‘Prediabetes’: are there problems with this label? no, we need heightened awareness of this condition! Diabetes Care 39 1472–1477. (doi:10.2337/dc16-1143)


Corrado A, Ferranti SM, Ferrì C, Ferrannini E, Antonelli A &fallah Pi 2014 Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. Clinical Therapeutics 36 1e181–1e185.


De Lany L & Herrington D 2007 Metabolic endotoxemia (MCO.0b013e3282efdebb)

Dianz MA & Schumman 2011 Advanced glycation end products are direct modulators of beta-cell function. Diabetes 60 2523–2532. (doi:10.2337/db10-1033)


Do OC, Vian LT, Gaisano HY & Thorn P 2014 The secretory deficit in islets from db/db mice is mainly due to a loss of responding beta cells. Diabetologia 57 1400–1409. (doi:10.1007/s00125-014-2226-8)

Dogán Y, Akarsu S, Ustundag R, Vilma E & Gurgoe MK 2006 Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators of Inflammation 2006 59206. (doi:10.1152/mi/2006/59206)


human intestinal myofibroblasts. *Journal of Immunology* **175** 5403–5411. (doi:10.4049/jimmunol.175.8.5403)


Zak KP, Popova VV, Mel’nichenko SV, Tron’ko EN & Man’kovskii BN 2010 The level of circulating cytokines and chemokines in the preclinical and early clinical stages of type Ia diabetes mellitus development. Terapevticheskii Arkhiv 82 10–15.

Received in final form 31 March 2017
Accepted 18 April 2017
Accepted Preprint published online 18 April 2017